These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32870235)

  • 61. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population.
    Martinez Navarro W; Ly L; Segal MS; Shukla AM
    Asia Pac J Ophthalmol (Phila); 2020; 9(4):374-375. PubMed ID: 32740071
    [No Abstract]   [Full Text] [Related]  

  • 62. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.
    Harrigan JJ; Hubbard RA; Thomas S; Riello RJ; Bange E; Mamtani M; Mamtani R
    J Gen Intern Med; 2020 Sep; 35(9):2826-2828. PubMed ID: 32542496
    [No Abstract]   [Full Text] [Related]  

  • 63. Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
    Jankowska EA; Sierpiński R; Tkaczyszyn M; Drozd M; Szachniewicz J; Duda-Sikuła M; Knysz B; Simon K; Szenborn L; Ponikowski P
    Kardiol Pol; 2020 Aug; 78(7-8):811-817. PubMed ID: 32687267
    [No Abstract]   [Full Text] [Related]  

  • 64. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
    Islam M
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):78. PubMed ID: 32723461
    [No Abstract]   [Full Text] [Related]  

  • 65. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE; Aronson JK
    BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
    [No Abstract]   [Full Text] [Related]  

  • 66. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19.
    Intson K; Kumar S; Botta A; Neckles R; Leung C; Jawaid A
    Swiss Med Wkly; 2020 Apr; 150():w20262. PubMed ID: 32347963
    [No Abstract]   [Full Text] [Related]  

  • 67. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
    Pimentel J; Andersson N
    Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Not throwing away our shot.
    Thorp HH
    Science; 2020 Oct; 370(6514):266. PubMed ID: 33060334
    [No Abstract]   [Full Text] [Related]  

  • 69. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 70. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
    Monte Serrano J; Cruañes Monferrer J; García-García M; García-Gil MF
    Med Clin (Barc); 2020 Sep; 155(5):231. PubMed ID: 32522372
    [No Abstract]   [Full Text] [Related]  

  • 72. Responding to Covid-19 - A Once-in-a-Century Pandemic?
    Gates B
    N Engl J Med; 2020 Apr; 382(18):1677-1679. PubMed ID: 32109012
    [No Abstract]   [Full Text] [Related]  

  • 73. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems.
    Saint-Raymond A; Sato J; Kishioka Y; Teixeira T; Hasslboeck C; Kweder SL
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1095-1101. PubMed ID: 32909843
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
    Koc G; Odabasi Z; Tan E
    J Clin Neuromuscul Dis; 2020 Sep; 22(1):60-62. PubMed ID: 32833728
    [No Abstract]   [Full Text] [Related]  

  • 75. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.
    Kalil AC
    JAMA; 2020 May; 323(19):1897-1898. PubMed ID: 32208486
    [No Abstract]   [Full Text] [Related]  

  • 76. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic.
    Scuccimarri R; Sutton E; Fitzcharles MA
    J Rheumatol; 2020 Jun; 47(6):783-786. PubMed ID: 32241801
    [No Abstract]   [Full Text] [Related]  

  • 77. ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.
    Stolbach AI; Mazer-Amirshahi M; Marino R; Nelson LS; Sugarman J
    J Med Toxicol; 2020 Jul; 16(3):342-345. PubMed ID: 32500283
    [No Abstract]   [Full Text] [Related]  

  • 78. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention.
    Tarek M; Savarino A
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):715-723. PubMed ID: 32780273
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
    Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD;
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093
    [No Abstract]   [Full Text] [Related]  

  • 80. Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.
    Schwartz JL
    N Engl J Med; 2020 Oct; 383(18):1703-1705. PubMed ID: 32966716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.